ESCMID Global 2025: IL-6 Outperforms Traditional Tests for Early Sepsis Detection

A BREAKTHROUGH study presented at ESCMID Global 2025 highlights IL-6 as a highly accurate early biomarker for sepsis in neonates, children, and pregnant women, three of the most vulnerable patient groups.

Click here to read more

Previous
Previous

‘Your story is important’: Anonymous health-care feedback tool launches in Alberta

Next
Next

Ontario new mother dies from infection two days after birth of healthy baby boy